News Â鶹´«Ã½ from Shionogi Pharma Latest news from Shionogi Pharma on News en-us Copyright 2024 News News Â鶹´«Ã½ from Shionogi Pharma 115 31 / /images/newswise-logo-rss.gif Pivotal Data for the Investigational Treatment PSD502 for Primary Premature Ejaculation in the U.S. to be Presented at Meeting /articles/pivotal-data-for-the-investigational-treatment-psd502-for-primary-premature-ejaculation-in-the-united-states/?sc=rsin /articles/pivotal-data-for-the-investigational-treatment-psd502-for-primary-premature-ejaculation-in-the-united-states/?sc=rsin Tue, 01 Jun 2010 08:00:00 EST Data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation (PE). These data were presented at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco. Shionogi Pharma